Spineway Past Earnings Performance

Past criteria checks 0/6

Spineway has been growing earnings at an average annual rate of 7.4%, while the Medical Equipment industry saw earnings declining at 2.5% annually. Revenues have been growing at an average rate of 21% per year.

Key information

7.4%

Earnings growth rate

100.0%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate21.0%
Return on equity-37.6%
Net Margin-66.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Spineway makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:37S Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2412-850
31 Mar 2412-760
31 Dec 2311-760
30 Sep 2311-560
30 Jun 2311-460
31 Mar 2310-450
31 Dec 229-350
30 Sep 227-240
30 Jun 226-230
31 Mar 226-230
31 Dec 215-220
30 Sep 215-220
30 Jun 215-320
31 Mar 215-820
31 Dec 205-1420
30 Sep 205-1420
30 Jun 205-1320
31 Mar 205-820
31 Dec 196-330
30 Sep 196-330
30 Jun 196-430
31 Mar 196-430
31 Dec 187-440
30 Sep 187-440
30 Jun 187-440
31 Mar 188-240
31 Dec 1710-140
30 Sep 179-130
30 Jun 179-130
31 Mar 177-230
31 Dec 165-320
30 Sep 165-220
30 Jun 166-220
31 Mar 166-220
31 Dec 156-230
30 Sep 156-230
30 Jun 155-230
31 Mar 155-220
31 Dec 145-220
30 Sep 146-120
30 Jun 146020
31 Mar 146020

Quality Earnings: 37S is currently unprofitable.

Growing Profit Margin: 37S is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 37S is unprofitable, but has reduced losses over the past 5 years at a rate of 7.4% per year.

Accelerating Growth: Unable to compare 37S's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 37S is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: 37S has a negative Return on Equity (-37.63%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/04 12:18
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Spineway SA is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arnaud GuérinPortzamparc BNP Paribas
Mohamed KaabouniPortzamparc BNP Paribas